Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Phase 2
372
about 9.8 years
18+
8 sites in CA, IL, MT +4
What this study is about
This trial is testing a treatment with patritumab deruxtecan, pembrolizumab, and other anticancer agents in people with high-risk early-stage triple-negative or hormone receptor-low positive/HER-2 negative breast cancer. The goal is to learn about the safety of these treatments and if people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Patritumab deruxtecan
- 2.Receive Pembrolizumab
- 3.Take Capecitabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, carboplatin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), Antineoplastic Agent [TC] (Immunologic Adjuvants), olaparib, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
oral (Oral Tablet), infusion, oral, injection, intravenous
Primary: Part 1: Number of Participants Experiencing an Adverse Event (AE), Part 1: Number of Participants who Discontinued Study Treatment Due to an AE, Part 2: Number of Participants Experiencing an AE, Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Secondary: Part 2: Event-Free Survival (EFS), Part 2: Overall Survival (OS)
Oncology